Trial Profile
A Phase II Randomized Trial of Prophylactic Gabapentin Plus Best Supportive Care Versus Best Supportive Care Alone for Patients Receiving Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Locoregionally-Advanced, HPV-Related Oropharyngeal Cancer: An Optima II Secondary Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Gabapentin (Primary)
- Indications Chemotherapy-induced damage; Radiation injuries
- Focus Therapeutic Use
- Acronyms PROGRESS Trial
- 25 Jan 2024 Planned End Date changed from 1 Sep 2023 to 1 Sep 2025.
- 25 Jan 2024 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2025.
- 26 Apr 2023 Planned End Date changed from 1 Jun 2023 to 1 Sep 2023.